GALVUS owner Contact Information online
from Novartis AG
GALVUS
The mark consists of the word "GALVUS" preceded by an oval with beveled edges partially overlapped by two arrows, one extending straight up and the other extending straight down; the color gray is intended to show shading or contrast only.
US serial number:85166857
Application filling date:Nov. 02, 2010
Register:Principal
Mark type:Trademark
Status:Registered. The registration date is used to determine when post-registration maintenance documents are due.
Status date:May 24, 2011
Publication date:Mar. 08, 2011
Standard character claim:No
Mark drawing type:3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S)
Foreign foreign registration number:554978
Foreign foreign registration date:Jan. 25, 2007
Foreign foreign application registration country:SWITZERLAND
Foreign foreign expiration date:Jan. 25, 2017
Goods and services:For: Pharmaceutical preparations for the prevention of disorders of the cardiovascular system and the metabolic system; Pharmaceutical preparations for the prevention of diabetes; Pharmaceutical preparations for the treatment of disorders of the cardiovas
Current owner owner name:Novartis AG
Current owner owner address:CH 4002
Basel
SWITZERLAND
Current owner legal entity type:CORPORATION
Current owner state or country:SWITZERLAND
Attorney name:Maury M. Tepper, III
Attorney email:mtepper@teiplaw.com
Attorney email authorized:No
Correspondent name address:MAURY M. TEPPER, III
TEPPER & EYSTER, PLLC
3724 BENSON DR
RALEIGH,
NORTH CAROLINA
UNITED STATES
27609-7321
Correspondent phone:919-861-8903
Correspondent email:mtepper@teiplaw.com
Correspondent fax:919-861-8913
Correspondent email authorized:No
Domestic representative name:Novartis Pharmaceuticals Corporation
Domestic representative phone:919-861-8903
Domestic representative fax GALVUS:919-861-8913
Latest trademarks
Popular owners
Glaxo Group Limited (173) Novartis AG (149) JOHNSON & JOHNSON (125) Millennium Pharmaceuticals, Inc. (54) Eli Lilly and Company (51) Windmill Health Products, LLC (46) Bayer Aktiengesellschaft (44) SANOFI (41) Wyeth LLC (41) Pfizer Inc. (39) Bristol-Myers Squibb Company (34) Forest Laboratories, Inc. (34) Vital Health Pharmaceuticals, Inc. (31) Primary Investments Group Limited (28) S. C. Johnson & Son, Inc. (28) MERCK SHARP & DOHME CORP. (27) Futurebiotics, LLC (26) MONSTER ENERGY COMPANY (19) Scott Riddell (17) Biocept, Inc. (16)Popular publication dates
Mar. 08, 2011 Mar. 15, 2011 Mar. 22, 2011 Nov. 16, 2010 Mar. 29, 2011 Apr. 19, 2011 Apr. 12, 2011 Oct. 19, 2010 Oct. 26, 2010 Oct. 05, 2010 Apr. 26, 2011 Feb. 15, 2011 Oct. 12, 2010 Jan. 25, 2011 Sep. 21, 2010 Jan. 11, 2011 Feb. 22, 2011 Nov. 23, 2010 Sep. 28, 2010 Apr. 05, 2011
